Safety, Efficacy, Pharmacokinetics & Pharmacodynamics of ARGX-117, a Therapeutic Antibody Targeting Complement Factor 2

Time: 12:20 pm
day: Track B - Day 1 AM


  • Evaluating how the ARGX-117 antibody has been engineered to have a long half life
  • Demonstrating that administration of ARGX-117 in healthy volunteers is safe and well-tolerated
  • ARGX-117 is being studied in adults with multifocal motor neuropathy in a Phase 2 clinical study